Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

EN
Press Releases
Home  >  News  >  Press Releases
OBESITY WEEK 2026 | OLATOREPATIDE PHASE III LIGHTEN STUDY SEX-SUBGROUP DATA RELEASED AS LATE-BREAKING ABSTRACT
Release Date:2026/11/16
Font Size

- Marked weight reduction and favorable metabolic improvements are observed in both men and women.

- Highly consistent efficacy-safety profile across genders, with robust and favorable gastrointestinal tolerability.



On November 15, 2026, Hansoh Pharmaceutical Group Co., Ltd. (“Hansoh Pharmaceutical”, 03692.HK) announced that, at Obesity Week held in Washington, DC, USA on November 14 (US Eastern Time), sex-subgroup analysis data from the Chinese Phase III weight management study(LIGHTEN)of Olatorepatide (HS-20094), a Hansoh Pharma's self-developed dual-biased glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonist, was presented as a Late-Breaking Abstract (LBA) poster. Building on the promising full-population data previously released at EASD 2026, this subgroup analysis further disclosed the efficacy and safety profiles among participants of different genders, providing new clinical evidence for individualized weight management in patients with overweight and obesity.



Obesity Week is one of the world’s most authoritative academic conferences in  the global field of obesity, co-hosted by The Obesity Society (TOS) and the International Association for the Study of Obesity (IASO). The LBA sessions are dedicated to the latest research of high innovation and major scientific significance. The inclusion of this sex-subgroup analysis of Olatorepatide as an LBA-Poster reflects high recognition by the global metabolism research community of the clinical value of this Chinese original dual-biased GLP1/GIP agonist for weight loss.


LBA-Poster details:

• Presentation Title: Sex-Specific Efficacy of Olatorepatide in Obesity: Greater Response in Women? China Phase 3 Insights[1]

• Session: Diabetes, Weight Management & Sex-Specific Outcomes

• Poster No.: poster-177

• Date/Time: 7:30–8:30 pm ET, November 14, 2026

• Presenter: Linong Ji (Peking University People's Hospital)


Study Methods:

This subgroup analysis was based on the complete dataset of the multicenter, randomized, double-blind, placebo-controlled Phase III trial (LIGHTEN). A total of 604 eligible Chinese adults with overweight or obesity were enrolled. Eligibility required a body mass index (BMI) ≥ 28 kg/m², or BMI between 24 and 28 kg/m² plus at least one weight-related comorbidity. Participants were randomized in a 1:1:1:1 ratio to receive once-weekly subcutaneous Olatorepatide at 5 mg, 10 mg, 15 mg, or placebo, for 48 weeks of treatment. The subgroup analysis primarily evaluated weight reduction, improvements in metabolic parameters, and safety profiles across male and female participants.


Core Efficacy Data:

After 48 weeks of treatment, Olatorepatide demonstrated statistically significant comprehensive benefits in both male and female participants. Reductions in body weight, waist circumference, waist-to-height ratio (WHtR), and fatty liver index (FLI) across all dose groups were significantly superior to the placebo group, with all between-group p values < 0.001. These findings confirm that Olatorepatide delivers robust weight loss and metabolic improvements in both genders with overweight or obesity.


While both men and women achieved favorable weight loss outcomes, female participants showed numerically greater responses on the above efficacy endpoints, as well as higher achievement rates for weight loss ≥15%, weight loss ≥20%, and waist-to-height ratio <0.5, indicating a trend of superior response among women.


Cross-Gender Safety Data:

No substantive differences in the overall safety profile were observed between the male and female subgroups. All adverse events during treatment were predominantly mild to moderate. Gastrointestinal adverse events(GIAEs) were transient and maintained at low overall incidence rates. Nausea occurred in 9.0% of female participants versus 5.0% of male participants; vomiting occurred in 5.4% of females versus 3.6% of males. The incidence of common GIAEs was substantially lower than the historical publicly available data for approved GLP1 agents. No participants in either gender subgroup discontinued treatment prematurely due to Olatorepatide-related adverse events, demonstrating excellent tolerability and medication adherence in both men and women with overweight or obesity.


The sex-subgroup data of Phase III LIGHTEN trial released at Obesity Week further enriches the evidence base for this Chinese original drug in the management of overweight and obesity across different genders.


About Obesity Week

Obesity Week is the largest and most influential academic conference globally in obesity research. It is co-hosted annually by The Obesity Society and the International Association for the Study of Obesity, bringing together leading researchers, clinicians, and industry practitioners worldwide to share cutting-edge basic research, clinical advances, and public health management experience in obesity. It serves as a core authoritative platform for the release of academic breakthroughs in obesity.


About Olatorepatide Injection

Olatorepatide Injection is a once-weekly subcutaneous dual-biased GLP1/GIP receptor agonist. It functions by modulating metabolic pathways governing appetite regulation, glucose metabolism, and energy balance. Olatorepatide is also currently in Phase III clinical development in China for the treatment of type 2 diabetes mellitus. In June 2025, Hansoh Pharmaceutical entered into a strategic collaboration with Regeneron, granting Regeneron exclusive overseas development and commercialization rights for the asset. In June 2026, the New Drug Application (NDA) for Olatorepatide Injection for long-term weight management in adults with overweight or obesity was accepted for review by the National Medical Products Administration (NMPA) of China.


Reference

[1] Ji, et al. Sex-Specific Efficacy of Olatorepatide in Obesity: Greater Response in Women? China Ph3 Insights. Poster-177, Obesity Week 2026.




About Hansoh Pharma

Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, metabolism, immunology, central nervous system (CNS) and anti-infectives. Hansoh Pharma has launched 7 innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).

Statements

1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.


Forward-Looking Statements

This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).